María Angélica Contreras

María Angélica Contreras

Auto-generated profile, based on publicly available information

María Angélica Contreras

Biotechnology and Biopharmaceutical Laboratory, Departamento de Fisiopatología, Facultad de Ciencias Biológicas, Universidad de Concepción, Víctor Lamas 1290, P.O. Box 160-C, Concepción 4030000, Chile

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2023 in Molecules
Verified
Journal Article
Open access
PDF file
MCMaría Angélica Contreras
María Angélica Contreras
YSYunier Serrano-Rivero
Yunier Serrano-Rivero
APAlaín González Pose
Alaín González Pose
JSJulieta Salazar-Uribe
Julieta Salazar-Uribe
MRMarcela Rubio-Carrasquilla
Marcela Rubio-Carrasquilla
EMErnesto Moreno
Ernesto Moreno
Nanobodies (Nbs) are single domain antibody fragments derived from heavy-chain antibodies found in members of the Camelidae family. They have become a relevant class of biomolecules for many different applications because of several important advantages such as their small size, high solubility and stability, and low production costs. On the other hand, synthetic Nb libraries are emerging as an attractive alternative to animal immunization for the selection of antigen-specific Nbs. Here, we present the design and construction of a new synthetic nanobody library using the phage display technology, following a structure-based approach in which the three hypervariable loops were subjected to position-specific randomization schemes. The constructed library has a clonal diversity of 108 and an amino acid variability that matches the codon distribution set by design at each randomized position. We have explored the capabilities of the new library by selecting nanobodies specific for three antigens: vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF) and the glycoprotein complex (GnGc) of Andes virus. To test the potential of the library to yield a variety of antigen-specific Nbs, we introduced a biopanning strategy consisting of a single selection round using stringent conditions. Using this approach, we obtained several binders for each of the target antigens. The constructed library represents a promising nanobody source for different applications.

10 September 2020 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
MCMaría Angélica Contreras
María Angélica Contreras
LMLuis Macaya
Luis Macaya
PNPedro Neira
Pedro Neira
FCFrank Camacho
Frank Camacho
AGAlaín González
Alaín González
OROliberto Sanchez Ramos
Oliberto Sanchez Ramos
TNFα is a pro-inflammatory cytokine that is a therapeutic target for inflammatory autoimmune disorders. Thus, TNFα antagonists are successfully used for the treatment of these disorders. Here, new association patterns of rhTNFα and its antagonists Adalimumab and Etanercept are disclosed. Active rhTNFα was purified by IMAC from the soluble fraction of transformed Escherichia coli. Protein detection was assessed by SDS–PAGE and Western blot. The KD values for rhTNFα interactions with their antagonists were obtained by non-competitive ELISA and by microscale thermophoresis (MST). Molecular sizes of the complexes were evaluated by size-exclusion chromatography-high performance liquid chromatography (SEC-HPLC). Surprisingly, both antagonists recognized the monomeric form of rhTNFα under reducing and non-reducing conditions, indicating unexpected bindings of the antagonists to linear epitopes and to rhTNFα monomers. For the first time, the interactions of rhTNFα with Adalimumab and Etanercept were assessed by MST, which allows evaluating molecular interactions in solution with a wide range of concentrations. Biphasic binding curves with low and high KD values (10−8 M) were observed during thermophoresis experiments, suggesting the generation of complexes with different stoichiometry, which were confirmed by SEC-HPLC. Our results demonstrated the binding of TNFα-antagonists with rhTNFα monomers and linear epitopes. Also, complexes of high molecular mass were observed. This pioneer investigation constitutes valuable data for future approaches into the study of the interaction mechanism of TNFα and its antagonists.

11 July 2021 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Closed access
PDF file
MCMaría A. Contreras
María A. Contreras
LMLuis Macaya
Luis Macaya
Viana Manrique SuárezViana Manrique Suárez
Viana Manrique Suárez
FCFrank Camacho
Frank Camacho
AGAlain González
Alain González
OROliberto Sanchez Ramos
Oliberto Sanchez Ramos

1 September 2021 in Journal of Biotechnology
Verified
Journal Article
Closed access
MLMaría J. Leiva
María J. Leiva
NPNatalie C. Parra
Natalie C. Parra
MCMaría A. Contreras
María A. Contreras
KTKaio C.S. Tavares
Kaio C.S. Tavares
LMLuis Macaya
Luis Macaya
RMRaquel Montesino
Raquel Montesino

23 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
MCMaría Angélica Contreras
María Angélica Contreras
LMLuis Alejandro Macaya
Luis Alejandro Macaya
PNPedro José Neira
Pedro José Neira
FCFrank Camacho
Frank Camacho
APAlaín González Pose
Alaín González Pose
OROliberto Sanchez Ramos
Oliberto Sanchez Ramos
TNFα is a pro-inflammatory cytokine that is a therapeutic target for inflammatory autoimmune disorders. Thus, TNFα antagonists are successfully used for the treatment of these disorders. Here, new association patterns of rhTNFα and its antagonists Adalimumab and Etanercept are disclosed. Active rhTNFα was purified by IMAC from the soluble fraction of transformed E. coli. Protein detection was assessed by SDS-PAGE and western blot. The K D values for rhTNFα interactions with their antagonists were obtained by non-competitive ELISA and by microscale thermophoresis. Molecular sizes of the complexes were characterized by SEC-HPLC. Surprisingly, both antagonists recognized the monomeric form of rhTNFα under reducing and non-reducing conditions, indicating unexpected bindings of the antagonists to lineal epitopes and to one protomer of rhTNFα. Binding curves of two phases with low and high K D values (10 −8 M) were observed during thermophoresis experiments, suggesting the generation of complexes with different stoichiometry, which were confirmed by SEC-HPLC. This pioneer investigation revealed interactions of rhTNFα with Adalimumab and Etanercept never described before, which constitute valuable data for future approaches into the study of their interaction mechanism.

2 October 2024 in Tropical Animal Health and Production
Verified
Journal Article
Closed access
PDF file
Viana Manrique SuárezViana Manrique Suárez
Viana Manrique Suárez
NGNicolás Gutiérrez
Nicolás Gutiérrez
AHAngela Hidalgo-Gajardo
Angela Hidalgo-Gajardo
EHEddy Ernesto González Horta
Eddy Ernesto González Horta
FHFlorence Hugues
Florence Hugues
JTJorge Roberto Toledo
Jorge Roberto Toledo